• Acting Assistant Professor, Global Health
Sarah Benki Nugent

Harborview Medical Center
325 9th Ave.
Seattle, WA 98104
United States

Phone Number: 
Select from the following:

Dr. Benki-Nugent received her PhD (Microbiology) and MS (Epidemiology) from the University of Washington. She has been involved in HIV research in Kenya since 2000. With expanded availability of pediatric HIV testing and treatment, survival in HIV-infected children has greatly improved; however best practices for optimizing the long-term neurodevelopmental trajectory and psychosocial well-being of HIV-infected children remain undefined. Dr. Benki-Nugent’s overarching research goals are to improve neurodevelopmental, growth, and health outcomes in HIV-infected children, and to develop scale-able strategies to improve child developmental outcomes in resource-limited settings. Her ongoing studies will determine the extent and correlates of neurocognitive impairment in HIV-infected children who either received antiretroviral therapy (ART) from infancy or who were HIV-diagnosed later in childhood. She is also involved in a study to determine the impact of home air pollution on respiratory illness, neurocognitive outcomes, and growth in HIV-infected children in Kenya.

Country Affiliations 
  • Spanish
Health Topics 
  • Child and Adolescent Health (incl. Pediatrics)
  • Environmental Health (incl. Climate Change)
  • Infectious Diseases
  • Non-communicable diseases

HIV pediatrics


Benki-Nugent S, Wamalwa D, Langat A, Tapia K, Adhiambo J, Chebet D, Okinyi HM, John-Stewart G. Comparison of developmental milestone attainment in early treated HIV-infected infants versus HIV-unexposed infants: a prospective cohort study. BMC Pediatr. 2017 Jan 17;17(1):24. doi: 10.1186/s12887-017-0776-1.

Sridharan G, John-Stewart G, Tapia K, Wamalwa D, Langat A, Okinyi HM, Adhiambo J, Chebet D, Okinyi HM, Maleche-Obimbo E, Karr CJ, John-Stewart G, Benki-Nugent S. High pre-ART viremia and wasting are associated with pneumonia in early treated HIV-infected Kenyan infants. Accepted, Journal of Pediatric Infectious Diseases.

Wamalwa D, Benki-Nugent S, Langat A, Tapia K, Ngugi E, Moraa H, Maleche-Obimbo E, Otieno V, Inwani I, Richardson BA, Overbaugh J, John-Stewart GC. Treatment interruption after 2-year antiretroviral treatment (ART) initiated during acute/early HIV in infancy: a randomized clinical trial. AIDS. May 12, 2016.

Benki-Nugent S, Eshelman, C, Wamalwa D, Langat A, Tapia K, Okinyi HM, John-Stewart, GC. Correlates of age at attainment of developmental milestones in HIV-infected infants receiving early antiretroviral therapy. Ped Inf Dis J. 2015 34(1):55-61.

Wamalwa D, Benki-Nugent S, Langat A, Tapia, K, Ngugi, E, Slyker J, Richardson BS, John-Stewart GC. Survival benefit of early infant antiretroviral therapy is compromised when HIV-1 diagnosis is delayed. Ped Inf Dis J. 2012 31(7):729-31.